Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing
cardiovascular morbidity and mortality and improving quality of life in cancer survivors …

Purpose of review Cancer is a common cause of morbidity and mortality in the USA. While
the association between venous thrombosis and malignancy is well established, arterial …

Immunomodulatory drugs (IMiDs) have improved survival of patients with multiple myeloma
(MM) and comprise the therapeutic backbone at all phases of therapy. Although well …

To date, five cancer treatment modalities have been defined. The three traditional modalities
of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two …

Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-
related adverse events negatively affecting myocardial structure and functions in patients …

Cancer-associated arterial thrombotic events (ATEs) are increasingly recognized in specific
malignancies and in association with the expanding armamentarium of novel …

Cancer patients have an increased risk of cardiovascular disease and, notably, a significant
prevalence of acute coronary syndrome (ACS). It has been shown that an elevated presence …

Over the past four decades, percutaneous coronary intervention (PCI) safety and efficacy
have significantly improved, particularly with the advent of the drug-eluting stent (DES). First …

Novel targeted cancer therapies have revolutionized oncology therapies, but these
treatments can have cardiovascular complications, which include heterogeneous cardiac …

Multiple myeloma (MM) patients are predominantly elderly with comorbidities that have an
impact on patient mortality and treatment decisions. We previously reported the patient …